Asthma

An association between antibiotic treatment in infancy and development of atopic asthma in childhood suggests an immune-mediated effect.

Ambient air pollution has become one of the world's greatest killers. But physicians still differ on their involvement in fighting it.

One inhalation product can be effective as a single maintenance and reliever therapy for asthma.

AstraZeneca announced that the first of its 2 phase 3 trials of benralizumab for severe COPD failed to meet its primary efficacy endpoint.

Researchers found that even high-performing hospitals can reduce over-utilization in bronchiolitis using novel de-implementation strategies.

Adding an anti-muscarinic to inhaled corticosteroid reduces asthma exacerbations, but possibly not more than other combinations.

The discovery could have researchers reconsidering treatment routes for pediatric patients.

The expanded indication was granted based on data from the IMPACT trial, in which it showed superiority to FF/VI and UMEC/VI.

The 10,000-plus participant IMPACT study reported the triple-combination therapy fared better in exacerbation reduction than FF/VI or FF/UMEC.

Three lung function trajectory categories were linked to were to 75% of COPD cases in a same-aged patient group by age 53.

A component in inflammatory pathogenesis including airway inflammation could serve as a biomarker in non-eosinophilic asthma.

Many physicians suggest upping a child’s dose of inhaled corticosteroids at the first symptoms of an asthma flare-up, but more research suggests the increased dosage makes no difference.

A new study helps explain why African-American and Puerto Rican children don’t respond as well to the common asthma drug, albuterol.

The first-of-its-kind research links inhaled corticosteroids to adrenal suppression in asthma and chronic obstructive pulmonary disease patients who have a genetic variant in the PDGFD gene.